Syngene's Margin Fell Four Points. Its Currency Line Rose Six Points of Revenue.

Syngene International's operating margin was 18% in the September quarter against 22% a year earlier, on revenue down 9%. The chief executive calls that "in line with expectations" and says it reflects, "primarily", "lower Zoetis revenues and forex hedge losses". The filings let us test only the second half of that sentence, and only partly: they report a net foreign-exchange line, not a hedge loss, and it rose from 1.3% to 7.4% of revenue from operations, a larger swing than the margin fall itself.

The idea in one sentence

A margin is only as clean as the lines inside it and the costs left outside it: at Syngene one currency line is larger than the whole fall, termination costs are booked below the margin, and the pre-operative cost of a US plant sits on the balance sheet.

The fact that breaks the assumption

Syngene's consolidated revenue from operations was ₹8,327 million (₹833 crore) against ₹9,106 million a year ago, down 9%, and up 13% on the June quarter. Operating EBITDA was ₹147 crore, a margin of 17.7% against 21.9% a year ago and 12.3% in Q1 (our arithmetic from the unrounded fact sheet; the press release rounds to 18%, 22% and 12%) ([PR], pp. 2, 8-9).

Now the line that most readers skip. Row (g) of the consolidated income statement is "Foreign exchange fluctuation loss, net": ₹614 million in the quarter, ₹118 million a year ago ([RS], p. 2). That is 7.4% of revenue against 1.3% (our arithmetic), a swing of 6.1 percentage points. The margin fell 4.2.

One line, followed

Does that line sit inside the margin? We checked against the fact sheet's own rows ([PR], p. 8). Q2 FY27: revenue ₹8,327 million, less material costs ₹1,986 million, staff costs ₹2,801 million, other direct costs ₹293 million, other expenses ₹1,158 million and the foreign-exchange loss of ₹614 million leaves ₹1,475 million, the operating EBITDA (our arithmetic). The same sum for Q2 FY26 gives ₹1,995 million, matching the fact sheet. So the currency loss is deducted before the margin is struck.

Put it back and the picture changes (our arithmetic):

*The fact sheet attaches its Note 11 to the year-ago "other expenses" line: ₹277 million net "written off as unrecoverable balances in receivables due to cumulative changes in foreign exchange rates" ([PR], p. 9). Whether to strip it out is a judgement; we show both versions.

On the CEO's own adjustment, the figure moves the same way. He says: "Adjusted for the forex hedge loss, the operating EBITDA margin would be in the mid-20s range for the quarter" (Siddharth Mittal, Managing Director and CEO, [PR], p. 3). Our 25.1% is consistent with that, but only if the whole net line is hedge loss. The filings do not split it ([RS], [PR], [IP]; see the header).

The mechanism: what sits inside the margin, and what does not

Three places in this quarter's accounts decide how clean the 17.7% is.

Inside: the currency line. It has not been a one-quarter event. The fact sheet's quarterly series ([PR], p. 9) shows the net foreign-exchange line at ₹48 million, ₹118 million, ₹233 million and ₹209 million across FY26, then ₹501 million and ₹614 million in FY27. The half-year total of ₹1,115 million (₹111.5 crore) is about 1.8 times the ₹61 crore the deck gives for all of FY26 (our arithmetic; [IP], p. 28). The cash-flow statement removes only ₹36 million of unrealised foreign-exchange gain from the half-year profit and does not otherwise say how much of the loss has been settled in cash ([RS], p. 4).

Inside, but quietly: the staff line. Staff costs were ₹2,801 million, against ₹2,814 million in Q1, while revenue rose from ₹7,360 million to ₹8,327 million. Staff costs fell from 38.2% to 33.6% of revenue (fact sheet, [PR], p. 9). Year on year, staff costs fell 9%, the same as revenue ([IP], p. 27). The company says "Manpower related cost optimization has been completed, while initiatives focused on non-manpower costs will continue" ([PR], p. 4). Our reading: staff cost behaves like a largely fixed line. It did not move when revenue rose 13% on the quarter, and it fell with revenue when revenue fell on the year.

Outside: the price of those cuts. Termination benefits are booked as "exceptional items", below operating EBITDA: ₹135 million before tax in Q1 and ₹67 million in Q2, so ₹202 million in the half ([RS], p. 8). The note gives the reason: "Considering the nature, significance and frequency of these benefits". They were also booked in the March 2026 quarter ([PR], p. 9), so this is the third quarter running. The press release excludes them from "PAT before exceptional item" of ₹38 crore; after them, profit after tax was ₹32 crore, against ₹67 crore a year ago and a loss of ₹9 crore in Q1 ([PR], p. 2).

Outside entirely: Bayview. Note 5 says Syngene USA Inc. acquired a biologics site in the USA from Emergent Manufacturing Operations Baltimore, LLC in the March 2025 quarter; the deck places Bayview in Baltimore ([IP], p. 17), and we take it to be the same site (our reading). The note says ₹4,876 million is accumulated in capital work in progress for it, "including Rs 1,246 million (31 March 2026: Rs 585 million) of pre-operative costs as management is of the view the same is eligible for capitalisation" ([RS], p. 8). The Bayview balance rose ₹829 million from ₹4,047 million at 31 March; that is 83% of the ₹1,002 million rise in consolidated capital work in progress, from ₹10,404 million to ₹11,406 million (our arithmetic; [RS], p. 3). The company reports its first manufacturing agreement for the site, with drug-substance manufacturing "expected to begin in the next financial year" ([PR], p. 3).

Our reading of the accounting: costs held in capital work in progress are not charged to operating EBITDA while the plant is being built, and the note does not say when depreciation starts. As a scale check only: the pre-operative balance of ₹1,246 million is 2.6 times the half-year consolidated profit before tax and exceptional items of ₹480 million (our arithmetic; a balance against a flow). We do not say the treatment is wrong: the statutory auditors' limited review report carries no qualification ("nothing has come to our attention"), and the note itself calls it management's view ([RS], pp. 8-9).

Where this breaks

• Half of the CEO's sentence cannot be tested. The filings say nothing about the size of the Zoetis shortfall. Revenue fell ₹779 million year on year ([RS], p. 2), and we cannot say how much of it is Zoetis. The deck's footnote on the same margin says only "lower revenues and forex hedge losses" ([IP], p. 6), without the name Zoetis.
• Our "before the currency line" margin is arithmetic, not a measure Syngene uses. The deck says clients are "concentrated in US, Europe & Japan" ([IP], p. 15), but no filing says in which currency Syngene bills. If part of the line is the recurring cost of hedging, a margin without it flatters. If the line is partly one-offs, it understates. The filings cannot settle which.
• Cash tells a separate story. Consolidated operating cash flow for the half-year was an outflow of ₹1,432 million (₹143 crore), against an outflow of ₹451 million a year ago, with other current liabilities falling ₹3,134 million on the balance sheet ([RS], pp. 3-4). Net cash fell to ₹1,392 crore from ₹1,800 crore at 31 March, a ₹408 crore drop (our arithmetic; the company's net-cash definition, [IP], pp. 27-28). Capital spending on property and capital work in progress was ₹2,099 million in the half. The statements do not say why liabilities fell.
• People. On 27 October the company disclosed that the CFO, Deepak Jain, has "decided to move on" for personal reasons. The filing says the transition timeline is "to be mutually agreed upon"; the press release says he continues at least until the close of the third quarter's results ([MC]; [PR], p. 4). The Head of Strategy and Corporate Development, Ajay Tandon, resigns from 30 October. The Heads of Chemistry and Biology, Subhendu Kumar and Priyaranjan Pattanaik, change from senior-management to non-senior-management status from the close of 27 October ([MC]), and the press release says they leave Syngene at the end of November and December as discovery services come under the Chief Scientific Officer ([PR], p. 3). Separately, Pramuch Goel, Head Corporate Affairs & Communications and an Executive Committee member, resigned with effect from 21 September ([SG]). Between 21 September and 27 October, then, the company has disclosed changes for four Executive Committee members and the CFO. That is a count, not a diagnosis; no filing gives a reason beyond "personal reasons", "other career opportunities" and the discovery reorganisation. A change of auditor is a smaller flag: the comparatives were reviewed by "the predecessor auditor" ([RS], p. 10), and the predecessor auditor’s conclusions are described as unmodified.
• One quarter is one quarter. Q2 is better than Q1 and worse than a year ago. The half-year, with revenue down 12% and margin 15% against 23%, is the harder number ([PR], p. 2). The press release headline says the margin "improves by 6 percentage points"; unrounded it is 5.4 (our arithmetic).

Why it costs the reader something

Anyone judging a contract research and manufacturing business by its margin alone will read this quarter as a four-point operating failure. The filings say something narrower: a currency line that has exceeded ₹200 million in each of the last four quarters, a cost base cut at a price booked below the line, and a US plant whose costs have yet to be tested against revenue. A reader who follows the margin and skips the notes would have missed all three. A reader who trusts the adjusted number without the split would be accepting the company's own description of the line as hedge loss.

The moat question is whether clients stay. The deck points to dedicated R&D centres, "Long-term strategic partnerships, typically extending for five years or more" among its collaboration models ([IP], p. 18), and about 400 active clients ([IP], p. 15). Lower revenue is not evidence that switching costs have weakened, but it is also not evidence that they hold. The filings carry no retention figure.

MoatSCORE (provisional, first-pass) 5.19 on our Moat Screener; the 2 August first-pass note, Syngene International Moat, predates this quarter and shows 5.01. For another margin read from this results season, see our Dr Reddy's piece.

What to watch

1. The transcript of the 28 October call, once filed, for the split of the foreign-exchange line and the size of the Zoetis shortfall.
2. Whether the net foreign-exchange line falls back in the December quarter, and what the CEO's "adjusted" margin is then.
3. The Bayview pre-operative balance next quarter, and the point at which it moves into depreciation.
4. The CFO's last day and successor.

Close: the one line

Row (g) of the income statement reads ₹614 million. The same row for the whole year to 31 March 2026 reads ₹609 million ([RS], p. 2). One quarter has now exceeded a year. The margin fell four points; the currency line, measured against revenue, rose six. Whether that line is a cost of the business or a loss that passes is the question the filings leave open, and the answer decides which Syngene margin to believe.

Sources

• [RS] Syngene, Q2 FY27 results, notes and auditors' review reports (NSE)
• [PR] Syngene, press release and fact sheet (NSE)
• [IP] Syngene, investor presentation, October 2026 (NSE)
• [MC] Syngene, change in management, 27 Oct 2026 (NSE)
• [SG] Syngene, change in senior management personnel, 21 Sep 2026 (NSE)
• [DR] Dr Reddy's Q2: Lenalidomide and the Base Business
• [MS] Moat & Margin, Moat Screener and Syngene International Moat

Educational research, not investment advice. Every figure above is drawn from Syngene's own filings, read from the primary documents on 28 October 2026; derived figures are our arithmetic, labelled as such. MoatSCORE read live from the Moat Screener on 28 October 2026 and provisional. No buy/sell recommendations, no price targets, no share prices. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.